Can Levothyroxine Cause Blood Sugar to Rise?

Levothyroxine, the synthetic form of thyroid hormone prescribed to tens of millions of people with hypothyroidism, can influence blood sugar levels, but whether it pushes them up or down depends heavily on context. At a properly calibrated dose that restores normal thyroid function, levothyroxine typically improves or leaves glucose metabolism unchanged. The picture shifts when the dose creeps too high, effectively mimicking an overactive thyroid, which is known to raise blood sugar. The relationship is more layered than a simple yes-or-no, because thyroid hormones sit at a crossroads of several glucose-regulating pathways in the liver, muscles, and gut.

How Thyroid Hormones Affect Blood Sugar

Thyroid hormones are deeply involved in how your body handles sugar, fat, and energy. They regulate carbohydrate metabolism through direct effects on gene expression in the liver and through cross-talk with other metabolic signaling pathways, including those that govern insulin sensitivity and bile acid processing.¹ In practical terms, thyroid hormones do two seemingly contradictory things at once: they increase glucose production by the liver, and they also help tissues pull glucose out of the blood.

On the production side, the active thyroid hormone T3 ramps up gluconeogenesis, the process by which the liver manufactures new glucose from non-sugar building blocks like amino acids. T3 does this by boosting the activity of key enzymes in that pathway and by increasing the liver’s uptake of amino acid precursors, providing both the raw material and the cellular energy needed to keep making glucose.² T3 also increases the expression of the glucose transporter GLUT2 in liver cells, which helps shuttle that newly made glucose into the bloodstream.³

There is even a brain-to-liver circuit involved. When T3 acts on certain neurons in the hypothalamus, it sends signals down sympathetic nerve fibers to the liver, directly boosting glucose output. In one animal experiment, delivering T3 to the brain’s paraventricular nucleus raised plasma glucose by about 29%, and cutting the sympathetic nerve supply to the liver completely blocked the effect.⁴

On the disposal side, T3 helps muscle cells absorb glucose. In lab studies, T3 quickly increased glucose uptake in muscle cells within 30 minutes, even before additional glucose transporters had moved to the cell surface.⁵ This dual action explains why having the right amount of thyroid hormone keeps blood sugar balanced: the liver makes glucose, and the muscles and other tissues clear it efficiently. When thyroid levels swing too high or too low, that balance breaks.

Why Hypothyroidism Itself Disrupts Blood Sugar

Before getting to what levothyroxine treatment does, it helps to understand what hypothyroidism does. People with an underactive thyroid often develop insulin resistance, meaning their cells respond less effectively to insulin’s signal to take up glucose. One reason is that the glucose transporter GLUT4, which normally moves to the surface of fat and muscle cells to let sugar in, does not traffic properly when thyroid hormone is low.⁶

Yet here is the counterintuitive part: despite higher insulin resistance, many hypothyroid patients do not show dramatically elevated fasting blood sugar. The liver compensates by producing less glucose in response to the elevated insulin circulating in the blood.⁶ So the numbers on a standard blood glucose test may look passable even while the metabolic machinery underneath is straining. This compensatory balance is fragile. It means that when you introduce levothyroxine and start raising thyroid hormone levels, multiple glucose-regulating systems shift at once, and the net direction depends on how much thyroid hormone you end up with.

What Levothyroxine Treatment Actually Does to Blood Sugar

For most people taking levothyroxine for an underactive thyroid, the medication brings thyroid levels back to normal, and that normalization tends to either improve or not significantly change glucose control. In patients with subclinical hypothyroidism treated with levothyroxine, one study found a significant drop in a standard measure of insulin resistance, suggesting the body’s cells became more responsive to insulin with treatment.⁷

Not every study, however, finds a clear improvement. In one trial of patients with overt hypothyroidism given levothyroxine, researchers found no significant changes in fasting blood glucose or insulin resistance markers after treatment.⁸ Another study that tracked metabolic markers over eight weeks of levothyroxine replacement also found no meaningful shift in insulin resistance indices.⁹

The mixed results are not necessarily contradictory. The degree of hypothyroidism, the starting level of insulin resistance, how long someone was hypothyroid before treatment, and the final thyroid hormone level achieved all matter. In people with mild subclinical hypothyroidism and mild metabolic disruption, the correction may produce a clear improvement. In people with more advanced hypothyroidism or who already have established metabolic syndrome, a few months of levothyroxine may not be long enough to reverse the damage.

When thyroid hormone treatment was studied in hypothyroid patients using a euglycemic clamp (a precise lab test for insulin action), bringing thyroid levels to normal significantly increased glucose disposal, meaning tissues cleared sugar from the blood more efficiently.¹⁰ That same study found that intentionally pushing healthy volunteers into mild hyperthyroidism did not produce the same improvement, hinting that the benefit is specific to correcting a deficit rather than to having more thyroid hormone in general.

When the Dose Is Too High

This is where the blood-sugar-raising concern becomes real. Levothyroxine over-replacement, where the dose pushes thyroid hormone levels above the normal range, effectively creates a state of mild hyperthyroidism. And hyperthyroidism is clearly associated with impaired glucose control: the liver overproduces glucose, insulin resistance in certain tissues increases, and blood sugar can climb.

Over-replacement is not rare. A large population study found that roughly one in five patients on levothyroxine had lab results consistent with over-treatment, and the likelihood of being over-treated rose with longer duration of therapy.¹¹ That means a substantial number of people on long-term levothyroxine may be getting more thyroid hormone than their body needs, sometimes without obvious symptoms. Subtle over-replacement can go undetected between annual blood tests, and during those intervals the excess thyroid hormone is doing exactly what it does in hyperthyroidism: ramping up hepatic glucose output and potentially undermining insulin sensitivity.

For someone without diabetes, mild over-replacement might nudge fasting glucose up modestly without ever crossing a diagnostic threshold. But for someone with pre-diabetes or type 2 diabetes, the same nudge could be enough to destabilize glucose control in a clinically meaningful way. The practical takeaway is that levothyroxine itself is not inherently a glucose-raising drug, but an incorrect dose absolutely can be.

A Gut Pathway That Connects Thyroid Hormones and Insulin

Recent research has uncovered a less obvious route through which thyroid hormones affect blood sugar, one that runs through bile acids and the gut. In the liver, thyroid hormone signaling through its receptor suppresses a gene involved in bile acid production, shifting the composition of bile acids in a way that dials down a receptor called FXR in the intestine. When intestinal FXR is suppressed, gut cells ramp up production of GLP-1, a hormone that stimulates insulin release from the pancreas.¹²

In animal models, blocking the GLP-1 receptor blunted the glucose-lowering effects of T3, confirming that this gut pathway plays a functional role and is not just a bystander.¹² The same research found that T3 levels correlated with GLP-1 levels and with the concentration of FXR-antagonistic bile acids in people with normal thyroid function, suggesting this mechanism operates in humans too.

This matters because GLP-1 is the same hormone that drugs like semaglutide and liraglutide mimic. It means that restoring thyroid hormone to normal levels through levothyroxine could, at least in theory, support insulin secretion through a pathway most people do not think about when they picture thyroid medication. It also suggests another way that too-low thyroid levels impair glucose handling: less thyroid hormone means less GLP-1, which means less insulin release after meals.

Levothyroxine in People Who Already Have Diabetes

Hypothyroidism and diabetes frequently coexist. The autoimmune form of thyroid disease (Hashimoto’s) shares immune pathways with type 1 diabetes, and both conditions can appear together in autoimmune polyglandular syndrome. In patients with this overlap, levothyroxine treatment has been associated with changes in insulin requirements, which underscores that thyroid hormone levels actively influence daily glucose management in people already on insulin.¹³

For people with type 2 diabetes taking levothyroxine, the clinical situation is nuanced. A review of dose-adjustment considerations across a patient’s lifetime noted that while diabetes does not directly change the levothyroxine dose someone needs, patients who have both conditions may be older or more medically complex, making careful dose titration especially important to avoid over- or under-treatment.¹⁴

In practical terms, if you have diabetes and start levothyroxine, your blood sugar may shift in either direction during the first weeks as your metabolism adjusts. Blood sugars may temporarily rise if the levothyroxine pushes the liver to produce more glucose before insulin sensitivity has had time to improve. Alternatively, some people see improvement, especially if insulin resistance from untreated hypothyroidism was a major factor. Closer glucose monitoring during the titration phase is sensible, regardless of which direction the initial shift goes.

Animal Evidence That Points Toward a Protective Effect

Some of the most striking findings come from animal studies, which obviously cannot be applied directly to humans but offer a window into biology. In mice, long-term levothyroxine supplementation enhanced glucose clearance from the bloodstream and lowered circulating glucose levels. The treated animals showed increased insulin levels and sustained activation of insulin-signaling pathways in target tissues like muscle and fat.¹⁵ The same study found that levothyroxine increased both the growth and turnover of insulin-producing beta cells in the pancreas, essentially maintaining a population of cells that were highly active insulin producers.

These animal results are interesting because they suggest that at appropriate levels, thyroid hormone may be genuinely supportive of glucose control rather than merely neutral. But “appropriate levels” is the critical qualifier. The doses used in animal experiments do not map neatly onto human dosing, and what counts as beneficial versus excessive thyroid hormone activity in a mouse may differ from a person. Still, the direction of the finding is consistent with the human data showing improved insulin sensitivity when hypothyroidism is corrected.

Subclinical Hypothyroidism and Pregnancy

Pregnant women occupy a special category here. Subclinical hypothyroidism during pregnancy, where thyroid-stimulating hormone (TSH) is mildly elevated but free thyroid hormones remain in the normal range, has been linked to a significantly higher risk of gestational diabetes. One study found that women with subclinical hypothyroidism had more than three times the odds of developing gestational diabetes compared to women with normal thyroid function.¹⁶

This finding adds another dimension to the levothyroxine-and-blood-sugar question. In pregnancy, the rationale for treating subclinical hypothyroidism with levothyroxine is partly to reduce obstetric complications, of which gestational diabetes is one. Here the medication is expected to reduce, not raise, the risk of glucose problems. Whether levothyroxine treatment fully eliminates the excess gestational diabetes risk in these women is still being studied, but the biological logic runs in a clear direction: leaving the thyroid under-treated carries its own glucose-related dangers.

What to Watch For in Practice

If you are starting levothyroxine or have recently had your dose changed, a few things are worth knowing about blood sugar specifically:

The dose-adjustment window: It takes about six to eight weeks for a new levothyroxine dose to reach a stable level in your body. Blood sugar fluctuations during this window, in either direction, do not necessarily mean the medication is bad for your glucose metabolism long-term.
TSH monitoring matters for glucose too: A suppressed TSH (below the normal range) is the lab hallmark of over-replacement. If your TSH stays low for months, you are living with excess thyroid hormone that can push glucose up, even if you feel fine otherwise.
Absorption variability: Taking levothyroxine with food, calcium supplements, or iron can change how much you absorb, effectively altering your dose from day to day. For someone whose blood sugar is already tightly managed, unpredictable swings in thyroid hormone absorption can translate to unpredictable glucose readings.
Seasonal TSH shifts: TSH tends to rise slightly in winter and fall in summer in many people. If your dose was set during one season, you may drift slightly into over-replacement during another, with corresponding subtle effects on metabolism.

The Autoimmune Overlap

Hashimoto’s thyroiditis, the most common cause of hypothyroidism in developed countries, is an autoimmune disease. Autoimmune conditions tend to cluster: someone with Hashimoto’s has a higher-than-average chance of also developing type 1 diabetes, celiac disease, or other autoimmune conditions. When these overlap, levothyroxine becomes one medication in a more complex regimen, and its effects on blood sugar interact with whatever else is going on immunologically and metabolically.

In autoimmune polyglandular syndrome type 3, where autoimmune thyroid disease and type 1 diabetes coexist, levothyroxine treatment has been associated with changes in insulin requirements.¹³ This is not because levothyroxine is toxic to beta cells or inherently raises glucose. Rather, it reflects how interconnected thyroid status and insulin dynamics are. When the thyroid piece changes, the insulin piece adjusts. Endocrinologists managing both conditions in the same patient typically coordinate thyroid and diabetes medications together, adjusting one with an eye on the other.

For people with type 2 diabetes, the connection is less about shared autoimmunity and more about shared metabolic terrain. Insulin resistance, dyslipidemia, and inflammation are common in both hypothyroidism and type 2 diabetes, and levothyroxine treats the thyroid component of that metabolic tangle without directly addressing the rest. Whether blood sugar improves as a result depends on how much of the insulin resistance was thyroid-driven versus driven by factors like excess body fat, diet, or genetic predisposition.

1
PubMed Central. Thyroid hormone regulation of metabolism
2
Life Sciences. Rapid and direct stimulation of hepatic gluconeogenesis by L-triiodothyronine (T3) in the isolated-perfused rat liver
3
Diabetes & Metabolism Journal. Links between Thyroid Disorders and Glucose Homeostasis
4
PubMed Central. Thyroid hormone modulates glucose production via a sympathetic pathway from the hypothalamic paraventricular nucleus to the liver
5
PubMed Central. Triiodothyronine acutely stimulates glucose transport into L6 muscle cells without increasing surface GLUT4, GLUT1, or GLUT3
6
PubMed Central. Cross-sectional analysis of insulin resistance in hypothyroid patients at rural teaching hospital: An endocrinal synergy
7
Diabetes. Improvement of Insulin Resistance and Cardiovascular Risk Factors with Treatment of Subclinical Hypothyroidism in Patients with Autoimmune Thyroiditis
8
PubMed Central. Effects of levothyroxine replacement therapy on insulin resistance in patients with untreated primary hypothyroidism
9
PubMed. The Effects of 8 Weeks of Levothyroxine Replacement Treatment on Metabolic and Anthropometric Indices of Insulin Resistance in Hypothyroid Patients
10
Clinical Science. Response of glucose disposal to hyperinsulinaemia in human hypothyroidism and hyperthyroidism
11
QJM: An International Journal of Medicine. Adequacy of thyroid hormone replacement in a general population
12
Nature Communications. Hepatic thyroid hormone signalling modulates glucose homeostasis through the regulation of GLP-1 production via bile acid-mediated FXR antagonism
13
PubMed Central. Levothyroxine and insulin requirement in autoimmune polyglandular type 3 syndrome: a real-life study
14
PubMed Central. Levothyroxine Dose Adjustment to Optimise Therapy Throughout a Patient’s Lifetime
15
PubMed Central. Levothyroxine enhances glucose clearance and blunts the onset of experimental type 1 diabetes mellitus in mice
16
PubMed Central. Outcomes With Levothyroxine Treatment in Early Pregnancy With Subclinical Hypothyroidism